Veradermics, Incorporated (MANE)
| Market Cap | 3.92B |
| Revenue (ttm) | n/a |
| Net Income | -98.80M |
| EPS | -15.84 |
| Shares Out | 41.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 826,640 |
| Open | 93.59 |
| Previous Close | 91.87 |
| Day's Range | 86.83 - 94.44 |
| 52-Week Range | 32.00 - 117.71 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 132.25 (+40.89%) |
| Earnings Date | Aug 6, 2026 |
About MANE
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDM... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for MANE stock is "Strong Buy." The 12-month stock price target is $132.25, which is an increase of 40.89% from the latest price.
News
Veradermics initiated with an Outperform at LifeSci Capital
LifeSci Capital analyst Rami Katkhuda initiated coverage of Veradermics (MANE) with an Outperform rating and $135 price target
Veradermics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Strong phase II/III results for an extended-release oral minoxidil tablet show rapid, consistent hair growth and high tolerability in male pattern hair loss, with female trials underway. Market research reveals high unmet need and willingness to adopt, especially among women.
Veradermics Transcript: Jefferies Global Healthcare Conference 2026
Pattern hair loss affects 80 million in the U.S., with significant unmet need and dissatisfaction with current treatments. Recent clinical trial data show strong efficacy and safety for a new oral therapy, with high adoption intent among physicians and patients. Upcoming milestones include additional male and first female data releases.
Veradermics initiated with a Buy at Needham
Needham initiated coverage of Veradermics (MANE) with a Buy rating and $136 price target The company’s VDPHL01, a late-stage ER minoxidil product candidate, is well positioned to become the first…
Veradermics to Present at Upcoming June Investor Conferences
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patt...
Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302' Study of VDPHL01 at the 2026 World Congress for Hair Research
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patt...
Veradermics price target raised to $135 from $120 at Citi
Citi raised the firm’s price target on Veradermics (MANE) to $135 from $120 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q1…
Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patt...
Veradermics Earnings release: Q1 2026
Veradermics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Veradermics Quarterly report: Q1 2026
Veradermics has published its Q1 2026 quarterly earnings report on May 12, 2026.
Veradermics reports Q1 net income ($27.2M) vs ($12.4M) last year
Cash, cash equivalents, and marketable securities totaled $390.8 million as of March 31, 2026, reflecting net proceeds from the company’s upsized initial public offering completed in February 2026. Su...
Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patt...
Veradermics 3.84M share Secondary priced at $100.00
The deal size was increased to 3.84M shares from 3.35M and priced below last closing price of $106.55. Jefferies, Leerink, Citi and Cantor Fitzgerald are acting as joint book running…
Veradermics Announces Pricing of Upsized Public Offering and Private Placement
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (“Veradermics”) (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative thera...
Veradermics announces offering of 3.35M shares of common stock
Veradermics (MANE) announced that it has launched a proposed public offering of 3.35M shares of common stock pursuant to a registration statement filed on Form S-1 with the SEC. All…
Veradermics Announces Launch of Public Offering
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (“Veradermics”) (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative thera...
Veradermics files to sell 3.35M shares of common stock
17:19 EDT Veradermics (MANE) files to sell 3.35M shares of common stock
Veradermics price target raised to $120 from $85 at Citi
Citi raised the firm’s price target on Veradermics (MANE) to $120 from $85 and keeps a Buy rating on the shares after the company announced positive topline results from Part…
Veradermics Transcript: Study result
Top-line results from a large phase II/III trial show VDPHL01 achieved significant hair growth and high patient satisfaction with a strong safety profile. Both once- and twice-daily regimens outperformed existing therapies, and market research indicates high intent to prescribe and use if approved.
Veradermics Press release: Study result
Veradermics issued a press release on April 27, 2026, disclosing material business information to investors.
Veradermics Slides: Study result
Veradermics has posted slides in relation to its latest quarterly earnings report, which was published on April 27, 2026.
Veradermics Registration statement: Registration filing
Veradermics filed a registration statement on April 27, 2026, providing details about a securities offering with the SEC.
Veradermics announces VDPHL01 met all primary, secondary endpoints
Veradermics (MANE) announced positive topline results from Part A of its randomized, double-blind, placebo-controlled Phase 2/3 clinical trial evaluating VDPHL01, a proprietary extended-release oral m...
Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302' Clinical Trial in Male Pattern Hair Loss
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair ...
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302' Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair ...